On Nov. 20, another milestone was reached in the ongoing legal cases regarding glyphosate. A Missouri state court granted final approval of Monsanto’s $7.25 billion nationwide class settlement of Roundup claims alleging non-Hodgkin’s lymphoma (NHL), Bayer said in a statement. The company says the settlement is designed to resolve current and future claims through a long-term claims program.
Bayer CEO Bill Anderson called final approval “a decisive milestone” in the company’s strategy to mitigate the risk of both pending and future Roundup litigation. Bayer, which acquired Monsanto in 2018, describes the settlement and the Supreme Court’s June ruling as “mutually reinforcing pillars” of that strategy.
The settlement covers people exposed to Roundup or other glyphosate-based products before Feb. 17, 2026, including farmers, landscapers and groundskeepers. Per-claimant payouts depend on exposure type, age at diagnosis and NHL type, and Monsanto funds the deal over 17 to 21 years. Bayer does not admit liability, and says the weight of scientific evidence supports glyphosate’s safety when used as directed.
Christopher A. Seeger of Seeger Weiss, counsel for current claimants in the settlement, has called it “one of the largest class recoveries in U.S. history.”
The approval is the latest in a run of wins for Monsanto this year:
- June 25: In Monsanto v. Durnell, the Supreme Court ruled 7-2 that federal pesticide law (FIFRA) preempts state failure-to-warn claims that would require a cancer warning EPA has not required.
- Oct. 29: A St. Louis County jury returned a unanimous defense verdict in Aretino v. Monsanto, the first Roundup trial since Durnell. With failure-to-warn claims barred, plaintiffs pursued design defect, fraud and negligence, and lost on all three.


